The P-II (ALTITUDE-AD) study assesses the safety & efficacy of sabirnetug (35mg/kg or 50mg/kg, Q4W) vs PBO to treat early AD patients (n=~540) in the US & Canada, to be expanded in EU & UK. The dosing was based on P-I (INTERCEPT-AD) study results. A P-I bioavailability study for SC formulation is expected in mid-2024
The P-I (INTERCEPT-AD) study in 62 individuals showed reduced amyloid plaque with sabirnetug vs approved therapies, low rates of ARIA-E & evidence of target engagement, confirming proof of mechanism
Sabirnetug, the first humanized mAb, has the ability of selective target engagement of AβOs that is a toxic form of Aβ which gets accumulated early in AD leading to synaptic dysfunction & neurodegeneration
Ref: Acumen Pharmaceuticals | Image: Acumen Pharmaceuticals
Related News:- Acumen Pharmaceuticals Presents P-I Trial (INTERCEPT-AD) Results of ACU193 for Early Alzheimer’s Disease at AAIC 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
